8 ms·
I just read in the NYT about an amyloid-clearing drug called BAN2401 that just reported results of Phase 2 trials (which test the safety and efficacy of a drug)
by alejohausner 8y ago
I just read in the NYT about an amyloid-clearing drug called BAN2401 that just reported results of Phase 2 trials (which test the safety and efficacy of a drug). The article starts by singing the praises of the drug, which substantially reduces amyloid scores. However, it then cautions that the drug's ability to slow down cognitive decline was small.
This supports the OP: amyloid may not be the culprit. In a phase 3 trial, the drug may not pan out.
source: nyti.ms/2JWjznT
- hcknwscommenter 8y agothe drug's ability to slow down cognitive decline was small but statistically significant and dose dependent. It is a huge deal. It is also interesting that the drug selectively targets protofibrils. This is interesting because A/Beta peptide is difficult to target because there is so much of it. Fibrils are difficult to target because they are insoluble. Selectively targeting protofibrils means the drug binds an accessible target and will not be titrated out by A/Beta peptide.